ORBIMED ADVISORS LLC 13D and 13G filings for ORIC Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-12-27 4:36 pm Sale |
2022-12-22 | 13D | ORIC Pharmaceuticals, Inc. ORIC |
ORBIMED ADVISORS LLC | 1,787,569 4.500% |
-425,002 (-19.21%) |
Filing |
| 2021-08-12 4:17 pm Sale |
2021-08-10 | 13D | ORIC Pharmaceuticals, Inc. ORIC |
ORBIMED ADVISORS LLC | 2,212,571 5.600% |
-254,721 (-10.32%) |
Filing |
| 2021-03-19 6:06 pm Sale |
2021-03-17 | 13D | ORIC Pharmaceuticals, Inc. ORIC |
ORBIMED ADVISORS LLC | 2,467,292 6.800% |
-298,425 (-10.79%) |
Filing |
| 2020-11-18 2:42 pm Unchanged |
2020-11-17 | 13D | ORIC Pharmaceuticals, Inc. ORIC |
ORBIMED ADVISORS LLC | 2,765,717 7.800% |
0 (Unchanged) |
Filing |
| 2020-05-01 4:15 pm Purchase |
2020-04-28 | 13D | ORIC Pharmaceuticals, Inc. ORIC |
ORBIMED ADVISORS LLC | 2,765,717 9.200% |
2,765,717 (New Position) |
Filing |